What is Xcovery?
Xcovery is a specialized biotechnology firm dedicated to the discovery and development of advanced oncology therapies. The company distinguishes itself by focusing on the creation of treatments that offer superior efficacy while minimizing the toxicity profiles often associated with traditional cancer care. By integrating rigorous scientific research with a patient-centric approach, Xcovery aims to address significant unmet medical needs within the global oncology market.
The company's portfolio is designed to improve the quality of life for patients, enabling them to manage their conditions with greater dignity. With a strong emphasis on small-molecule and biologics discovery, Xcovery is positioned as a key player in the pharmaceutical landscape, bridging the gap between complex molecular science and practical, life-extending clinical applications.
How much funding has Xcovery raised?
Xcovery has raised a total of $48.9M across 8 funding rounds:
Series A
$2.4M
Series B
$6M
Debt
$2.1M
Multiple Rounds
$38.1M
Debt
$350K
Series A (2011): $2.4M, investors not publicly disclosed
Series B (2012): $6M, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Series C (2014): $2.4M, investors not publicly disclosed
Series D (2014): $15M backed by Brace Pharma and EMS S/A
Debt (2014): $675K, investors not publicly disclosed
Private Equity (2014): $20M led by Betta Pharmaceuticals
Debt (2020): $350K supported by PPP
Key Investors in Xcovery
Brace Pharma
Brace Pharma Capital is an investment firm focused on innovative therapies for diseases that have significant unmet medical needs and limited treatment options.
EMS S/A
Founded in 1950 and headquartered in Hortolândia, Brazil, EMS Pharma is a domestic pharmaceutical company and a major distributor of pharmaceuticals in Brazil.
Betta Pharmaceuticals
Betta Pharmaceuticals is a leading Chinese pharmaceutical company dedicated to developing and commercializing innovative oncology products to meet high unmet medical needs.
What's next for Xcovery?
With the support of its recent strategic investment, Xcovery is poised to accelerate its clinical development programs and expand its research capabilities. The company's forward-looking strategy involves navigating the regulatory landscape to bring its lead candidates through late-stage trials and toward commercialization. By leveraging its existing partnerships with industry leaders, Xcovery is well-positioned to scale its operations and enhance its market presence.
Future milestones will likely focus on the successful completion of ongoing NDA reviews and the advancement of its proof-of-concept clinical trials. As the company continues to refine its therapeutic pipeline, it remains committed to its core mission of delivering innovative, less toxic oncology solutions to the global healthcare community, ultimately aiming to redefine the standard of care for cancer patients worldwide.
